Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11838668 | 0.83 | KMT2A (0.48) | ALOX5L3MBTL1ACHEMAPTCNR1 | |
| SCHEMBL14093005 | 0.83 | ALOX5 (0.49) | ALOX5CYP2C19LMNAALDH1A1L3MBTL1 | |
| SCHEMBL28957129 | 0.81 | AOC3 (0.47) | — | |
| SCHEMBL28957128 | 0.81 | AOC3 (0.47) | — | |
| SCHEMBL5132748 | 0.81 | HTT (0.40) | ALOX5NR3C2L3MBTL1 | |
| SCHEMBL4310166 | 0.81 | HTT (0.40) | ALOX5NR3C2L3MBTL1 | |
| SCHEMBL22190392 | 0.81 | BCAT2 (0.36) | — | |
| SCHEMBL5462636 | 0.81 | BCAT2 (0.55) | CYP2C19LMNAL3MBTL1 | |
| SCHEMBL2089538 | 0.81 | BCAT2 (0.55) | CYP2C19LMNAL3MBTL1 | |
| SCHEMBL5470948 | 0.81 | BCAT2 (0.55) | CYP2C19LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080173808-A1 | PROCESS AND DEVICE FOR RESPONSE NORMALIZED LIQUID CHROMATOGRAPHY NANOSPRAY IONIZATION MASS SPECTROMETRY (RNLC-NSI-MS) | SCHERING CORPORATION | 2008-07-24 | — | — | US | claimed |
| US-12616685-B2 | Concomitant administration of glucocorticoid receptor modulator relacorilant and CYP2C9 substrates | CORCEPT THERAPEUTICS INCORPORATED (US) | 2026-05-05 | — | — | US | disclosed |
| US-12528790-B2 | Amide derivative having antiviral activity | SHIONOGI & CO., LTD. (JP) | 2026-01-20 | — | — | US | disclosed |
| WO-2025085756-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-04-24 | — | — | WO | disclosed |
| CN-118792241-B | Culture medium, method, model and application of primary hepatocyte culture 3D liver model | 上海合珀生物科技有限公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-118792241-A | Culture medium, method, model and application of primary hepatocyte culture 3D liver model | 上海合珀生物科技有限公司 | 2024-10-18 | — | — | CN | disclosed |
| EP-4414376-A2 | NOVEL DEPSIPEPTIDE AND USES THEREOF | Novobiotic Pharmaceuticals, LLC (US) | 2024-08-14 | — | — | EP | disclosed |
| US-20230382893-A1 | AMIDE DERIVATIVE HAVING ANTIVIRAL ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2023-11-30 | — | — | US | disclosed |
| EP-4238960-A1 | AMIDE DERIVATIVE HAVING ANTIVIRAL ACTIVITY | Shionogi & Co., Ltd (JP) | 2023-09-06 | — | — | EP | disclosed |
| EP-4157274-A1 | CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATOR RELACORILANT AND CYP2C9 SUBSTRATES | Corcept Therapeutics Incorporated (US) | 2023-04-05 | — | — | EP | disclosed |
| WO-2021242916-A1 | CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATOR RELACORILANT AND CYP2C9 SUBSTRATES | CORCEPT THERAPEUTICS INCORPORATED (US) | 2021-12-02 | — | — | WO | disclosed |
| EP-3916004-A1 | NOVEL DEPSIPEPTIDE AND USES THEREOF | Novobiotic Pharmaceuticals, LLC (US) | 2021-12-01 | — | — | EP | disclosed |
| US-20210231677-A1 | TRACELESS IMMOBILIZATION OF ANALYTES FOR SAMDI MASS SPECTROMETRY | NORTHWESTERN UNIVERSITY | 2021-07-29 | — | — | US | disclosed |
| EP-3301109-B1 | NOVEL DEPSIPEPTIDE AND USES THEREOF | NOVOBIOTIC PHARMACEUTICALS LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| CN-112458158-A | CYP2C9 gene segment containing 373C > T mutation, protein segment coded by same and application thereof | 杨杰孚 | 2021-03-09 | — | — | CN | disclosed |
| WO-2020141734-A1 | METHOD FOR PREPARING CHIRAL GAMMA-LACTAM COMPOUND AND METAL COMPLEX THEREFOR | 기초과학연구원 | 2020-07-09 | — | — | WO | disclosed |
| WO-2019237019-A9 | TRACELESS IMMOBILIZATION OF ANALYTES FOR SAMDI MASS SPECTROMETRY | NORTHWESTERN UNIVERSITY (US) | 2020-06-11 | — | — | WO | disclosed |
| WO-2012088156-A1 | INHIBITORS OF CYTOCHROME P450 | GILEAD SCIENCES, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2009106882-A1 | CYTOCHROME B5 KNOCKOUT ANIMAL MODELS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-09-03 | — | — | WO | disclosed |
| US-20080173808-A1 | PROCESS AND DEVICE FOR RESPONSE NORMALIZED LIQUID CHROMATOGRAPHY NANOSPRAY IONIZATION MASS SPECTROMETRY (RNLC-NSI-MS) | SCHERING CORPORATION | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382893-A1 | AMIDE DERIVATIVE HAVING ANTIVIRAL ACTIVITY | ZC3HAV1, ZC3HAV1L, IFNAR1 | ALOX5 2844/4885NR3C2 509/4885CYP2C19 2090/4885 |
| US-12528790-B2 | Amide derivative having antiviral activity | IFNAR1, NSUN2, ZC3HAV1 | ALOX5 4076/4885NR3C2 270/4885CYP2C19 2298/4885 |
| US-12616685-B2 | Concomitant administration of glucocorticoid receptor modulator relacorilant and CYP2C9 substrates | CYP3A43, CYP2D6, CYP3A4 | ALOX5 1947/4885NR3C2 26/4885CYP2C19 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.